Lava Therapeutics (Netherlands)
Lava Therapeutics is a Netherlands-based company developing its Gammabody® bispecific gamma delta T cell engager platform to fight cancer.
Last updated September 16, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Lava Therapeutics is a company in Utrecht, Netherlands, focused on developing its Gammabody® platform to transform cancer therapy. The Gammabody® platform generates bispecific gamma delta T cell engagers that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 T cells. This approach is designed to complement natural tumor recognition, direct Vγ9Vδ2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade. The company states that to date it is the only company developing bispecific gamma delta T cell engaging antibodies for the treatment of cancer. Its board of directors includes chair Kapil Dhingra, M.B.B.S., and director Jay Backstrom, M.D., M.P.H.
History
Lava Therapeutics is a company in Utrecht, Netherlands. It focuses on developing its Gammabody® platform to transform cancer therapy. The Gammabody® platform generates bispecific gamma delta T cell engagers that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 T cells. This approach is designed to complement natural tumor recognition, direct Vγ9Vδ2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade. The company states that to date it is the only company developing bispecific gamma delta T cell engaging antibodies for the treatment of cancer. In 2025, Lava Therapeutics was the subject of a tender offer by XOMA Royalty, and the company announced exceeding the minimum condition in the tender offer and its intent to delist from Nasdaq.
Products and positioning
To date, we are the only company developing bispecific gamma delta T cell engaging antibodies for the treatment of cancer.
Gammabody® platform
Generates bispecific gamma delta T cell engagers that specifically activate Vγ9Vδ2 T cells.
Recent events
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/lava-therapeutics-netherlands · Editorial policy · How profiles are compiled